T-cell Therapy Market Size, Share, Growth, Trends, Statistics and Regional
Forecast to 2028
The global T-cell therapy market size was valued at USD 4.6 billion in 2020 and is expected to
expand at a compound annual growth rate (CAGR) of 20.2% from 2021 to 2028. With the approval
of Yescarta, Kymriah, and Tecartus, several companies have shifted their business models from the
development of protein and small molecule-based treatments to adoptive therapies. This has driven
strategic investments by the public as well as private agencies in this space, thereby driving the
market for T-cell therapy.
Currently, the cancer immunotherapy arena widely employs T-cell based mechanism, due to a higher
success rate. As of June 2020, more than 350 CAR-T clinical trials have been registered in China.
This data indicates the growing importance of Chimeric Antigen Receptor therapy in cancer
treatment. Also, the majority of operating players are investing in CD19 CAR-T therapies to enhance
their market positions in the near future.
For Right Perspective & Competitive Insights, Request a Sample @:
The expanding gene therapy marketspace is playing a vital role in the success of CAR-T therapies.
With increasing investments in the gene therapy arena, this space is expected to witness constant
growth. The companies such as Novartis AG are actively engaged in exploring the potential of CAR-
T-based gene therapies for several chronic indications.
Top Key Players studied in T-cell Therapy Market:
Gilead Sciences Inc.
TCR2 Therapeutics Inc
Bluebird Bio Inc.
Global T-cell Therapy Market Segmented by Product:
Global T-cell Therapy Market Segmented by Region:
North America (U.S.; Canada; Mexico), Europe (Germany; U.K.; France; Italy; Russia; Spain etc.), Asia-
Pacific (China; India; Japan; South